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Abstract 
Aims 
This study aims to evaluate the efficacy of SLT as a treatment option in black patients 
with open angle glaucoma and to distinguish which patients are most likely to 
respond to SLT. 
Methods 
The study is a retrospective case-series of black patients collected at St. John’s Eye 
Hospital in Johannesburg.  Data from 46 eyes were collected from the files of 
patients who had had SLT at least six months previously. The data collected included 
demographic factors, ocular characteristics and intraocular pressure (IOP) before and 
at each visit after selective laser trabeculoplasty (SLT). The data were analysed 
statistically firstly by comparing the pre-SLT IOP with the average post-SLT IOP, and 
secondly by Kaplan-Meir analysis of the duration of IOP control post-SLT. 
Results 
The mean age of participants was 58,3 years. The mean follow up time was 8 
months (range1 week to 33 months). The mean pre-SLT IOP was 20,7mmHg and the 
mean post–SLT IOP was 17,8mmHg. The change in IOP was statistically significant 
(p<0,001). The mean reduction in IOP was a 12% reduction from baseline. The mean 
duration of IOP control by Kaplan-Meier analysis was 13 months. The only 
demographic or ocular factor associated with a greater reduction in IOP was 
trabecular meshwork pigmentation. Patients with higher pigmentation had a median 
IOP reduction of 23,0% and those with low pigmentation a median reduction of 
3,5%. 
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Conclusion 
SLT resulted in a statistically significant but modest reduction in IOP in black 
glaucoma patients. The average reduction in IOP was 12% from baseline. High 
trabecular meshwork pigmentation was associated with a statistically significantly 
greater reduction in IOP. 
Introduction 
Glaucoma is a disease of the optic nerve characterised by progressive visual field loss 
and characteristic structural changes. The structural changes include thinning of the 
retinal nerve fibre layer and excavation of the optic nerve head. The most important 
risk factor for progression of glaucoma is raised intraocular pressure (IOP).1 IOP can 
be controlled by medication, laser trabeculoplasty, surgery or a combination of 
treatments.1  
The level of IOP is the result of a balance between aqueous production by the ciliary 
body and aqueous drainage mostly through the trabecular meshwork (TM). The 
outflow resistance of the TM is increased in open angle glaucoma, so that aqueous 
drainage is only able to match aqueous production at a raised IOP.1 The raised IOP in 
turn leads to progressive visual field loss and structural changes to the optic nerve.1 
Laser trabeculoplasty aims to reduce the outflow resistance at the TM resulting in 
reduced IOP and preservation of visual field. 
Laser trabeculoplasty was first described by Wise and Witter in 1979. They used an 
argon laser to place thermal burns on the TM. Although the mechanism of action of 
argon laser trabeculoplasty (ALT) is controversial, the glaucoma laser trial established 
the efficacy and limitations of ALT.2  
Latina and Park developed selective laser trabeculoplasty (SLT) in 1997. SLT uses a 
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laser with very low energy settings and a very short pulse duration. The energy is 
only absorbed by pigmented cells and causes photolysis. As the laser is selective 
unlike ALT there is no thermal coagulation of tissues. Only the pigmented cells of the 
TM are affected so SLT is less destructive to the surrounding tissues than ALT.3  
Glaucoma is the second most common cause of blindness worldwide, including 
Africa where glaucoma accounts for up to 30% of cases of blindness. The annual 
incidence of glaucoma in Africa is estimated to be 400 cases per million population.3 
The burden of glaucoma in Africa is exacerbated by difficulties with its management 
in part due to difficult social circumstances. Management of glaucoma in this setting 
using medication can be difficult due to long distances and the cost of travel to 
collect medication. The cost of medications and lack of a regular supply of 
medications to health care facilities add to problems with medical treatment. It can 
also be difficult to convince patients of the need to use medications despite no 
improvement in their vision.5 SLT in these circumstances has significant advantages 
over medication as compliance is easier, and the patient does not have to collect 
medication on a monthly basis. 
In light of the above information, further information regarding the effectiveness of 
SLT in patients of African descent and in a hospital serving many patients with 
difficult social circumstances would be useful for clinicians as well as health care 
managers in decision making in order to reduce the burden of glaucoma in Africa. 
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Literature review 
The most widely accepted theories for the mechanism of action of ALT are the 
mechanical and the cellular theories. According to the mechanical theory, ALT causes 
thermal coagulation of the treated potion of the TM. This leads to scarring and 
contraction of the treated portion of the TM, which pulls on the untreated portion of 
the TM opening the inter-trabecular spaces, facilitating outflow through the 
untreated portion of the TM. ALT causes shrinkage of collagen, separation of 
trabecular sheets and traction on Schlemm's canal.2 According to the cellular theory, 
the laser burns recruit macrophages which phagocytose debris in the TM and de-
bulk the extracellular matrix, decreasing outflow resistance. 2 
The glaucoma laser trial (GLT) established the efficacy of ALT. The GLT demonstrated 
a mean drop in IOP of 9mmHg. At 2 years follow up, 44% of eyes had a controlled 
IOP after ALT alone, while 70% were controlled on ALT and Timolol drops. After 7 
years, patients treated with ALT had a 1,2mmHg greater reduction in IOP than those 
treated with medication, as well 0,6dB better performance on visual field testing.2 
Despite the encouraging results of the GLT there is debate about the long term 
effects of ALT. While some studies including the GLT show good efficacy at 7 years, 
other studies show loss of efficacy, with increasing IOP 2 years after treatment.6 Fink 
et al found that success rates fell from 71% at 33 months post ALT to 45% at 42 
months.6 For patients who fail to maintain IOP control, re-treatment with ALT has 
been shown to be less successful than the initial treatment. There is also a risk of a 
rise in IOP after ALT, presumably due to coagulative destruction of a large part of the 
TM.6 The potential harmful effect of repeated ALT causing too much scarring of the 
TM is demonstrated by Gaasterland and Kupfer who induced glaucoma in monkeys 
by applying ALT to the entire TM.6  
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The energy delivered by SLT is 1000 times less than that delivered by ALT due to the 
very short duration of the laser pulse.7 The 532nm wavelength and short pulse 
duration were chosen so that the energy is only absorbed by the pigmented cells of 
the TM, sparing the surrounding non-pigmented cells from any thermal effects.3 As 
there is no coagulative damage, crater formation, or disruption of trabecular beams 
or endothelial cells, the mechanical theory does not apply to SLT.2 The fine structure 
of the TM is preserved so SLT is less destructive than ALT.2 SLT works only by cellular 
mechanisms. The death of pigmented cells after SLT causes release of cytokines, 
which in turn cause release of gelatinases and metalloproteinases, macrophage 
recruitment, and repopulation of the TM by new cells. This results in remodelling of 
the TM, reducing IOP without observable mechanical or thermal damage to the 
recruited area.8  
The clinical efficacy of SLT in reducing IOP in patients with open angle glaucoma was 
first demonstrated by Latina et al in 1998.9  He treated 53 eyes and demonstrated a 
drop in IOP of at least 3mmHg in 70% of eyes and a mean drop of 5,8mmHg with a 6 
month follow up. Other researches have demonstrated reductions in IOP, ranging 
from 3,9 to 8mmHg.2 A study of 460 eyes by Kaulen showed an average reduction in 
IOP of 23%.2  
SLT has been shown to produce similar reductions in IOP to ALT. Damji et al 
compared SLT to ALT in a randomised prospective trial of 176 eyes. They found no 
statistically significant difference in IOP between the two groups during a 1 year 
follow up period.  
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10 Similar conclusions have been obtained by Prinazar and Tabak.5 
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SLT has similar efficacy to medical treatment with the prostaglandin analogue 
latanoprost in the primary treatment of POAG. Nager et al11 performed a 
randomised prospective study comparing SLT with latanoprost 0,005%. The following 
table gives the percentage of patients achieving a 20% or 30% reduction in IOP after 
a mean follow -up of 10 months.11  
 >20% IOP reduction > 30% IOP reduction 
360 degree SLT 82.00% 59.00% 
Latanoprost 90.00% 78.00% 
Table 1: Summary of the results of the study by Nager comparing response rates 
for SLT and latanoprost 11 
 
The difference in IOP percentage reduction between the latanoprost group and the 
360 degree SLT group was not statistically significant. The authors concluded that 
360 degree SLT might be a useful primary therapy for ocular hypertension and open 
angle glaucoma.11 McIlraith et al12 compared the efficacy of 180 degree SLT as 
initial therapy or as an alternative to medical therapy with latanoprost in a 
prospective trial with 100 patients. There was an average reduction in IOP of 
8,3mmHg in the SLT group compared to 7,7mmHg in the latanoprost group. The 
difference was not statistically different. This study suggests that SLT is safe and 
effective as primary treatment for open angle glaucoma.12  
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SLT can also be offered to patients with medically controlled glaucoma in order to 
reduce the medication burden. Francis et al3 did a prospective case-series of 66 eyes 
which were controlled on medical therapy. He applied 180 degrees of SLT and found 
the average number of medications required dropped from 2,8 at baseline to 0,7 at 
6 months and 1,5 at 1 year.3  
SLT has also been used in patients with glaucoma that is not medically controlled on 
maximal topical medical therapy. In these cases, SLT can avoid surgical management 
and the risk and side effects that are associated with it. Geyer et al performed SLT on 
50 such patients. They found that 66% of patients had avoided surgery at 6 months, 
and 55% had avoided surgery at 12 months. Mean IOP reduction was 21% at 6 
months and 20% at 12 months.3  
The side effects of SLT encountered by Latina and Park include mild anterior 
chamber inflammation in 83% of patients, which resolved after 5 days in all cases.9 
They also found an IOP increase of 5mmHg or more in 25% of patients within 1 hour 
of SLT.9 The IOP spike resolved with medication in all cases within 24 hours and did 
not persist in any cases.  
There are cases of persistent IOP elevation in patients with a hyperpigmented TM or 
pigment dispersion glaucoma. In these cases the IOP elevation is usually persistent, 
and these patients often require surgical management.3  
There are many racial differences in the incidence, age of onset, rate of progression 
and optic disc configuration. Black patients have a higher incidence of POAG than 
white patients, tend to develop glaucoma 10 years younger than white patients, and 
tend to progress more rapidly.13 These differences as well as differences in ocular 
pigmentation may lead to different responses and side effects after SLT in black 
patients. Studies on ALT have suggested that it is more effective in patients with 
14 
 
more pigment in the TM. Pigment in the TM may prevent laser/tissue interaction, 
reducing the efficacy of SLT in patients with hyperpigmented angles.11 Studies on 
Chinese eyes and African American eyes have shown similar response rates to white 
patients. This however needs further confirmation.7  
The Advanced Glaucoma Intervention Study (AGIS) looked at treatment options in 
uncontrolled glaucoma on maximal medical therapy. One cohort of patients received 
ALT and if unsuccessful a trabeculectomy first followed by another trabeculectomy if 
still uncontrolled (ATT cohort). The second cohort received a trabeculectomy first, 
followed by ALT if still uncontrolled, followed by another trabeculectomy (TAT 
cohort). Patients were followed up for between 4 and 7 years. They found a highly 
statistically significant difference in outcome between black and white patients in 
the two treatment groups. Black patients had a better outcome over the 7 years if 
they received ALT first (ATT group). White patients had a better visual outcome if 
assigned to the trabeculectomy first (TAT) group.14 This result highlights different 
responses in white and black patients to laser trabeculoplasty and trabeculectomy, 
and the need to assess the effectiveness of SLT in black patients. 
Study hypothesis 
SLT effectively lowers IOP in black patients. 
Study aims 
This study aims to evaluate the efficacy of SLT as a treatment option in black patients 
with open angle glaucoma and to distinguish which patients are most likely to 
respond to SLT. 
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Study objectives 
The primary objective is to compare the pre-SLT IOP with the average post-SLT IOP in 
order to determine the overall effect of SLT on IOP, and to determine if the effect is 
statistically as well as clinically significant in black patients.  
The secondary objective is to determine if any ocular or SLT treatment factors are 
associated with a greater or lesser response to SLT. The factors to be assessed 
include trabecular meshwork pigmentation, POAG versus PCE glaucoma, 180 versus 
360 degrees of SLT, number of medications, glaucoma severity, corneal thickness and 
total SLT energy used.  
Methods 
Study design 
The study is a retrospective case-series of patients collected at St. John's Eye 
Hospital in Johannesburg. Approval was obtained through the Medical Advisory 
Committee of Chris Hani Baragwanath Hospital and ethics approval was obtained 
through the Committee for Research on Human Subjects of the University of the 
Witwatersrand. 
All doctors working at St. John's Eye Hospital were informed about the study and 
were asked to refer any patient who had had SLT at least 6 months prior for inclusion 
in the study, irrespective of the outcome after the treatment and the response to 
treatment in order the avoid referral bias. Patients who were referred for 
participation in the study were assessed for eligibility according to the inclusion 
criteria (see table 2). Prior to inclusion in the study patients were informed of the 
purpose of the study, were given an opportunity to decline to participate and were 
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made aware that their participation would in no way affect their treatment. Those 
who agreed to participate were asked to sign a consent form.  
6 months or longer post-SLT follow up 
Good compliance with reliable follow up and consistent use of prescribed 
medications 
African decent and not of mix race 
Good visualisation of the trabecular meshwork with clear media 
Diagnosis of either primary open angle glaucoma or PCE glaucoma 
No previous glaucoma filtration surgery 
Age 18 years or older 
Table 2: Inclusion criteria 
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Laser techniques 
SLT treatment at St John's is generally administered by one of the registrars rotating 
through the glaucoma clinic. A Lumenis Coherent Selectra 7000 laser attached to slit 
lamp is used. This is a frequency doubled, q-switched Nd:YAG laser emitting at 
532nm. The pulse duration is 3ns, the spot size 0,4mm and the energy can be set in 
0,1mj increments between 0,2-1,7mJ.   
After the application of a drop of local anaesthetic, a Latina SLT contact lens is 
applied to the cornea. After the trabecular meshwork has been visualised, 45-55 
treatment shots are applied to each quadrant of the trabecular meshwork. The laser 
energy is initially set to 0.7mJ. If 'champagne bubbles' are seen, the energy is 
reduced in 0,1mJ increments until they are no longer seen. If no 'champagne 
bubbles' are seen, the energy is increased until they are seen and then reduced by 
0,1mJ. Either 180 degrees or 360 degrees of the trabecular meshwork is treated, 
depending on the clinician. Post-SLT, the patients were instructed to continue their 
usual glaucoma treatment. 
Data Collection 
Data were collected from the patient's file directly onto the 'SLT Study patient 
record.' The first page of the record included ocular details and details of the SLT 
treatment itself. Ocular details included the patient's lens status, type of open angle 
glaucoma, and the amount of trabecular meshwork pigmentation. This information 
was obtained from the patient's file, except in cases where it was not recorded or 
not available. Trabecular meshwork pigmentation was not routinely recorded in the 
patient’s file. Gonioscopy was performed at the time of data collection in order to 
grade the amount of trabecular meshwork pigmentation. Trabecular meshwork 
pigmentation was graded on the Beker and Schaffer scale. 0 indicates no pigments, 1 
indicated slight browning of the TM, 2 indicates definite browning of the TM, and 3 
18 
 
indicates heavy infiltration of the TM with dark brown pigment.15 
Patient’s stage of glaucoma was categorised into mild, moderate, or severe based on 
the best available information. If a visual field was available, those with a mean 
deviation (MD) greater than -10 were graded as mild, those with a MD between -10 
and -15 were graded as moderate, and those with an MD less than -15 were graded 
as severe. If no visual field was available, the cup to disc ratio was used. A ratio less 
than 0,5 was graded as mild, between 0,5 to 0,8 was moderate, and greater than 0,8 
was severe.   
The details of the SLT treatment were recorded. The total energy delivered was 
calculated by multiplying the number of treatment shots by the energy used per 
shot. The number of degrees of angle treated, either 180 degrees or 360 degrees 
was also recorded. 
Where possible, data was collected for the 3 months prior to administration of the 
SLT in order to get a more accurate measure of the average pre-treatment IOP. In all 
cases the best estimate of average pre-treatment SLT was used. If the only available 
pre-treatment IOP was the IOP on the day of treatment, then that IOP was used. All 
IOPs collected were done so on the same medication that the patient was on at the 
time SLT treatment. If a medication was added, or removed, no further IOP 
measurements were collected.  
The study had a minimum post SLT follow up of 6 months. However if a patient's 
medication was increased or they went for surgery within the 6 months, they were 
still included in the study, with the time which the SLT controlled the IOP recorded. It 
was important to include these patients, as excluding them would have biased the 
study.  
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Unfortunately as available medications in the hospital change, patient's medication 
was changed from time to time. During the assessment time for many patient the 
available prostaglandin analogue changed from latanoprost to bimatoprost. The 
effect of this change was assumed to be negligible if a medication was changed to a 
medication in the same class. Similarly, the supply of combination drops was variable 
so a change from two separate bottles of medication to a similar combination was 
also assumed to have a negligible effect on the IOP. If a patient defaulted treatment 
or was put on extra treatment for a period of less than 3 months, the IOPs while on 
the different treatment were disregarded, but were collected once the patient had 
been back on their pre-SLT treatment for at least a month.  
Data analysis-primary objective 
The data was captured onto a spreadsheet with one section allocated to 
demographic, ocular and laser treatment parameters, and one section allocated to 
the various IOP measurements at each time point after the SLT treatment. 
As the study was retrospective and the follow up time periods varied with each 
patient, each time point contained different numbers of readings, and no time point 
had a reading for every patient. It was therefore not possible to draw a simple graph 
of IOP versus time. It was also not possible to use  the percentage change of IOP at a 
time period (say 6 months) to assess the effect of the SLT treatment as those 
patients who did not respond were often started on additional medication within 1 
month of SLT so their 6 month IOP was unknown. This limitation was overcome by 
analysing the data in two ways, firstly by determining the average post-SLT IOP, and 
secondly by defining IOP control in order to construct a Kaplan-Meier plot to assess 
the months of IOP control post-SLT. 
The average post-SLT IOP gave a reasonable estimation of the overall effect of the 
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treatment for the full follow up period for each eye. Normality was assessed and a 
paired sample t test performed using Sofastats version 1.4.3 to compare the pre-SLT 
IOP with the average post-SLT IOP. 
The clinical significance of SLT was further assessed by determining the average 
percentage change in IOP from baseline for each eye.  
Secondly, a Kaplan-Meier analysis was performed. Control of IOP was defined as a 
10% reduction of IOP from baseline at 75% or more of visits. Using this definition the 
time in months for which IOP was controlled was identified. The end point was the 
time post SLT where the patient did not meet the above definition of controlled. The 
patient was marked as censored if IOP was controlled through the entire available 
follow up period, and the time of follow up was recorded. These data was entered 
into MedCalc version 14.10.2 to obtain a Kaplan-Meier plot.  
Data analysis-secondary objective 
Ocular and laser factors were analysed using the percentage change in average IOP 
post SLT as an outcome measure, as well as by Kaplan-Meier plots of duration of IOP 
control as another outcome measure.  
Continuous variables were converted into categorical variables in order to simplify 
statistical analysis. The amount of energy delivered during SLT was divided into less 
than 50mJ, 50-60mJ and more than 60mJ. The central corneal thickness was divided 
into corneas less than 510 microns and those greater than 510 microns.  
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Certain grades of TM pigmentation and had very few numbers in the group, so it was 
preferable to combine groups. TM pigmentation was categorised as either low 
(Becker and Schaffer grade 0-1) or high (Becker and Schaffer grade 2-3).  The number 
of glaucoma medications also was categorised into two groups (those using 0-1 
medications, and those using 2-4 medications) for similar reasons.  
An independent samples t-test was used to analyse the average percentage change 
in IOP when comparing patient characteristics which fell into two categories with 
adequately normal data. A t-test was therefore used to compare pseudocapsular 
exfoliation (PCE) glaucoma with POAG; 180 degrees of treatment with 360 degrees; 
patients on 0-1 medications with those on 2-4 medications; and corneal thickness 
less than 510microns with corneal thickness greater than 510microns. When 
comparing low trabecular meshwork pigmentation with high pigmentation, a Mann 
Whitney test was used as the data was not sufficiently normal.  
An analysis of variance (ANOVA) test was used to analyse the average percentage 
change in IOP when comparing patient categories with more than two variables and 
adequately normal data. ANOVA was therefore used to compare the average 
percentage change in IOP for each of the glaucoma stages (mild, moderate, or 
severe); and for each of the categories of SLT energy used.  
Kaplan-Meier plots were used to assess the duration of IOP control post-SLT for each 
of the categories. IOP control was defined as an IOP decrease of at least 10% from 
baseline at 75% or more of clinic visits. A logrank test was used to analyse the 
Kaplan-Meier plots for statistically significant differences between categories.  
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Data analysis – SLT technique 
The amount of energy used per spot was compared between the patients with low 
TM pigmentation and those with high TM pigmentation. The greater the 
pigmentation of the TM, the more energy is absorbed for each laser spot. A t-test 
was performed to assess if there was a difference in energy use between these two 
groups as the data was sufficiently normal. 
Results 
Subjects 
Mean age was 58,3 years (standard deviation 13.6). Mean central corneal thickness 
was 0.509mm (standard deviation 0.041). The mean number of glaucoma 
medications used was 1,8 (range 0-4). Mean pre-SLT IOP was 20,7mmHg (standard 
deviation 4.3). 4 eyes had PCE glaucoma while 41 had POAG. 
16 eyes had 180 degrees of SLT while 29 had 360 degrees. 
The mean follow up time was 8 months, but ranged from 1 week (for a patient who 
did not respond) to 33 months. 
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Primary objectives 
Analysis of pre-SLT IOP and average post SLT IOP 
 Mean 95% 
Confidence 
interval 
Standard 
deviation 
Min Max 
Pre-SLT IOP 20,7 mmHg 19,4 to 21,9 4,3 13 31 
Average 
post-SLT IOP 
17,8 mmHg 16,7 to 18,9 3,7 11 26 
Change in 
IOP 
-2,8 mmHg  
(-12,1%) 
-4.2 to -1.5  4.5 -13,8 4 
Table 3: Summary of the results of the effect of SLT on IOP 
 
A histogram of the pre-SLT IOP and post-SLT IOP is shown. The skew and kurtosis of 
the graphs are within acceptable ranges so the data is sufficiently normal for an 
analysis with a paired sample t-test. 
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Fig 1: Histogram of the pre-SLT IOP. The horizontal axis shows the pre-SLT IOP. The 
vertical axis shows the proportion (P) of eyes with a particular IOP measurement. 
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Fig 2: Histogram of average post-SLT IOP.  
 
The results of the paired sample t test is shown graphically with a histogram of the 
change in IOP as well as with a dot and line plot of the pre-SLT and post-SLT IOP. 
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Fig 3: The results of the paired sample t test. The horizontal axis indicates the 
change in IOP post-SLT in mmHg The vertical axis shows the proportion (P) of 
cases which experienced a particular change in IOP.  
 
27 
 
 
Fig 4: Dot and line representation of the change in IOP after SLT for each patient 
with a bar chart showing the mean pre and post-SLT IOP. 
 
The paired samples t test showed that the difference between pre-SLT IOP and 
average post-SLT is statistically significant (p<0,001). 
The percentage change in IOP was assessed to determine the clinical significance of 
SLT treatment. A graph of the results is shown in figure 5. The average percentage 
change in IOP after SLT ranged from a 49% decrease to a 29% increase. The mean 
change in IOP was a decrease of 12,1%, while the standard deviation was 19,3%. 
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Fig 5: Histogram of the percentage change in IOP. 
 
In terms of responder rates, 17% of patients achieved a 30% or greater reduction in 
IOP. 39% of patients achieved a 20% or greater reduction in IOP. 4% of eyes 
experienced a 20% or greater increase in IOP. 
The overall Kaplan-Meier survival curve for all patients is shown in figure 6. IOP 
control was defined as a 10% or greater decrease in IOP from baseline at 75% or 
more of clinic visits.  The total sample size was 46 eyes. 27 (59%) of cases were 
uncontrolled at a time point and so were labelled as an 'event.' 19 cases (41%) were 
controlled at all points of the study and so were censored. Mean duration of IOP 
control was 13 months (95% confidence interval 8,5-17,8 months). 
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Fig 6: Kaplan-Meier plot showing the percentage of patients with controlled IOP 
at each time point in the study. The area between the grey curves indicate a 95% 
confidence interval. Censored data (i.e. patients who were controlled until the 
end of the follow up period and who therefore have an unknown duration of IOP 
control) are indicted by a vertical tick on the main curve. The number at risk 
table below the graph indicates the number of patients remaining in the study at 
each time point. 
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Secondary objectives 
The following tables summarise the results of the analysis of the various ocular and 
laser factors. The Kaplan-Meier graphs are included only when the results are of 
special interest. 
 
 Analysis of average percentage 
change in IOP post -SLT  
Analysis of months of IOP control 
post SLT (IOP reduction of 10% from 
baseline at 75% of clinic visits) by 
Kaplan-Meier analysis 
Low 
trabecular 
meshwork 
pigmentation 
(14 cases) 
Median -3.6% 
Average rank 
19,2 
 
 
 
P=0,011 
(Mann 
Whitney U 
test) 
Mean duration of IOP 
control = 8.5 months  
(95% CI = 2 to 15 
months)  
 
 
P = 0,2 
(logrank 
test) 
High 
trabecular 
meshwork 
pigmentation 
(15 cases) 
Median -23,0% 
Average rank 
11,1 
Mean duration of IOP 
control = 15,4 months  
(95% CI = 7 to 24 
months)  
Table 4: Results of statistical analysis comparing the high TM pigmentation group 
and the low TM pigmentation group 
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Fig 7: Kaplan-Meier plot comparing months of IOP control post-SLT for patients 
with low and high trabecular meshwork pigmentation. 
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 Analysis of percentage change in 
IOP post -SLT 
Analysis of months of IOP 
control post SLT (IOP reduction 
of 10% from baseline at 75% of 
clinic visits) by Kaplan-Meier 
analysis 
POAG  
(41 cases) 
Mean -15,3% 
(SD 19,0%) 
 
 
 
 
P=0,187  
(Independent 
samples t test) 
Mean duration of 
IOP control = 12,9 
months  
(95% CI =8 to 18)  
 
 
 
P =0,8275 
(logrank test) PCE 
glaucoma  
(4 cases) 
Mean -24,0% 
(SD 21,0%) 
Mean duration of 
IOP control = 3.1 
months  
(95% CI = 0,4 to 6 
months)  
Table 5: Summary of statistical analysis comparing POAG with PCE glaucoma 
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180 degrees 
of SLT 
(16 cases) 
Mean -14,1% 
SD 22% 
 
 
 
P=0,659 
(Independent 
samples t test) 
Mean duration of 
IOP control = 18,7 
months  
(95% CI = 11 to 26 
months)  
 
 
 
P = 0,0351 
(logrank test) 
360 degrees 
of SLT  
(29 cases) 
Mean -16,7% 
SD 16,8% 
Mean duration of 
IOP control = 8,4 
months  
(95% CI = 4 to 13 
months)  
Table 6: Summary of statistical analysis of180 degrees of SLT and 360 degrees of 
SLT 
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Fig 8: Kaplan-Meier plot of the proportion of eyes with controlled IOP at each 
time interval showing a significant difference between patients who received 180 
degrees of SLT compared to 360 degrees of SLT. 
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 Analysis of percentage change in 
IOP post -SLT  
Analysis of months of IOP 
control post SLT (IOP reduction 
of 10% from baseline at 75% of 
clinic visits) by Kaplan-Meier 
analysis 
0-1 
medications 
(17 cases) 
-8,60% 
SD 19,7% 
 
 
 
P = 0,351 
(Independent 
samples t test) 
Mean duration of 
IOP control = 
4.9months  
(95% CI = 2 to 8 
months)  
 
 
 
P = 0,0739 
(logrank test) 
2-4 
medications  
(28 cases) 
-14,10% 
SD 19,0% 
Mean duration of 
IOP control = 7,0 
months  
(95% CI =5 to 9 
months)  
Table 7: Summary of the statistical analysis comparing patients using 0-1 
medications with those using 2-4 medications  
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 Analysis of percentage change in 
IOP post -SLT  
Analysis of months of IOP control post 
SLT (IOP reduction of 10% from 
baseline at 75% of clinic visits) by 
Kaplan-Meier analysis 
Mild  
(22 cases) 
Mean -16,0%  
SD 20,8% 
 
 
 
 
P=0,987 
(ANOVA) 
Mean duration of IOP 
control = 12,2 months  
(95% CI = 6 to 19 months)  
 
 
 
 
P = 0,6278 
(logrank 
test) 
Moderate  
(8 cases) 
Mean -16,8%  
SD 24,3% 
Mean duration of IOP 
control = 10,2 months  
(95% CI = 2 to 18 months)  
Advanced  
(16 cases) 
Mean -17,0%  
SD14,6% 
Mean duration of IOP 
control = 7,8 months  
(95% CI =5 to 10 months )  
Table 8: Summary of the statistical analysis comparing mild, moderate and severe 
glaucoma  
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Corneal 
thickness 
<510 
microns  
(19 cases) 
Mean -6,8% 
 SD 18,1% 
 
 
P=0,430  
(Independent 
samples t test) 
Mean duration of 
IOP control = 12,8 
months (95% CI = 
6 to 19 months)  
 
 
P = 0,3707 
(logrank test) 
Corneal 
thickness 
>510 
microns  
(18 cases) 
Mean -11,9%  
SD 20,8% 
Mean duration of 
IOP control = 10,0 
months (95% CI = 
4 to 16)  
Table 9: Summary of statistical analysis comparing eyes with corneas less than 
510 microns with those thicker than 510microns 
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Total SLT 
energy less 
than 50mJ  
(10 cases) 
Mean -6,1% 
SD 19,7% 
 
 
 
P=0,599 
 (ANOVA) 
Mean duration of 
IOP control = 
10,2months  
(95% CI = 3 to 17 
months)  
 
 
 
P = 0,9331 
(logrank test) 
Total SLT 
energy 
between 50 
and 60 mJ 
(18 cases) 
Mean -11,8% 
SD 16,3% 
Mean duration of 
IOP control = 12 
months  
(95% CI = 5 to 19 
months)  
Total SLT 
energy 
greater than 
60mJ  
(17 cases) 
Mean -13,7% 
 SD 20,8% 
Mean duration of 
IOP control = 14 
months  
(95% CI = 6 to 21 
months)  
Table 10: Summary of statistical analysis of corneal thickness and total SLT energy 
used 
SLT technique 
Mean energy per treatment spot was 0,7mJ for patients with low TM pigmentation, 
and 0,67mJ for those with a high TM pigmentation (P=0,475)  
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Discussion 
Primary objectives 
This study found a statistically significant reduction in IOP after treatment with SLT. 
The mean absolute decrease in IOP in this study was 2,9mmHg and the mean 
percentage decrease in IOP was 12,1%. SLT is therefore a useful adjunct in the 
management of open angle glaucoma at St. John's Eye Hospital.  
The following table summarises the reduction in IOP (both the absolute and the 
percentage reduction) of the most significant published studies on SLT.  
 Patients Pre-SLT IOP Mean reduction in IOP 
Damji 1999 18 22,8mmHg 4,8 mmHg at ( 21%)(6 months)7 
Damji 2006 36 23,8 mmHg 6,1 mmHg at (27%) at 6 months 
10 
McIlraith 2006 74 26 mmHg 8,3 mmHg (31%) average IOP 
after 1 year follow up12 
Hodge 72 23,8 mmHg 5,8mmHg (24,4%) at 1 year17 
Song 94 17,6mmHg 2,1 mmHg (11,9%) at 10 
months17 
Table 11: Summary of the IOP reduction in the major SLT trials 
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Although direct comparison of the IOP reduction across studies is not possible given 
the differences in study design, population groups, stage of glaucoma and baseline 
IOP, the substantial difference between this study outcomes and those in the 
literature needs consideration.  
The mean pre-SLT of 20,7 is a relatively low in comparison to most of the studies so 
one would expect a lower drop in IOP. Similar to this study, the study by Song had a 
low pre-SLT IOP of 17,6 and also had relatively modest results, similar to this study. 
Another possibility which needs to considered is the possibility of racial differences 
in the response to SLT. Most of the studies mentioned earlier were performed on a 
Caucasian population. Given the racial differences in glaucoma recognised in the 
AGIS study, this possibility needs to be considered. Juzych did a retrospective review 
of 41 patient after SLT. He found no difference in the effectiveness between white 
patients and African Americans.16 Of Nager's study of 167 patients, 22% were of 
African descent. There were no racial differences in terms of IOP response in his 
study.11 The above studies suggest that racial differences are unlikely to be a factor 
in the modest IOP reduction in this study. 
At St. John's SLT is usually performed by a registrar rotating through the glaucoma 
clinic. The registrars are usually new to SLT and are performing their first few 
treatments. As they are early in their learning curve, they may not be using the 
optimal energy level and may struggle to visualise the TM adequately to place the 
laser spots accurately. In order to assess the technique of SLT delivery, the energy 
used for the low TM pigmentation group was compared with that of the high TM 
group. Less energy is required in patients with a darkly pigmented trabecular 
meshwork to produce the ‘champagne bubble’ appearance which is used to find the 
optimal energy setting.8 The mean energy per spot was however found to be similar 
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in both groups (0,7mJ for low pigmentation vs 0,67mJ for high pigmentation, 
P=0,475) suggesting that the energy selection in patients in this study was not 
optimal. This may be one of the factors responsible for the relatively modest IOP 
reduction in this study.  
Determining the target IOP or percentage drop in IOP required to prevent the 
progression of glaucoma is challenging, but this would give an indication of the 
clinical significance of the IOP reduction caused by SLT. The early manifest glaucoma 
trial was a large study of 255 patients with early glaucoma. The trial showed that a 
decrease in IOP of 25% reduced the risk of progression from 62% to 45%. The 
collaborative initial glaucoma treatment study had very low rates of progression. 
They decreased IOP by 38% in the medical group and 46% in the surgical group. The 
target IOP reduction therefore varies between 25% and 50%, depending on various 
patient factors. In this study the percentage of patients reaching a 30% or greater 
decrease in IOP was 17%, where as a 20% decrease was reached in 39% of eyes. 
Although many patients may not meet the above target percentage decrease in IOP 
with SLT alone, the IOP reduction for those who did respond was achieved without 
the burden, side-effects, and costs of medications, or the risks of surgical treatment.  
The Kaplan-Meier plot showed a rapid decrease in proportion of patients controlled 
in the first 3 months with only 48% of patients controlled at 3 months, dropping off 
to 39% at 5 months. This is best explained by there being a high proportion of 
patients who did not respond to the SLT. In the study by Nager, it was noted that 
most patients who are going to respond to SLT will respond within 3 months.11 The 
non-responders cause the steep initial decline in the Kaplan-Meier graph. However 
patients who do respond to the treatment tend to have a sustained benefit and 
remain controlled, causing a levelling off of the graph.  
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Secondary objectives 
The change in IOP post-SLT was statistically significantly greater for patients with 
high TM pigmentation than for those with low TM pigmentation. In the Kaplan-
Meier analysis, although there was a longer duration of IOP control for patients with 
high TM pigmentation the difference did not reach statistical significance. The effect 
of TM in other studies is inconsistent. Chen et al found a statistically significantly 
greater IOP reduction at 7 month for patients with higher TM pigmentation18 while 
Hodge and McIlraith found no difference.19, 12 Considering that the mechanism of 
action of SLT is thought to occur by disruption and fragmentation of intracytoplasmic 
melanosomes, and the ensuing inflammatory response there is a reasonable 
theoretical basis for TM pigmentation to affect outcomes.  
High TM pigmentation increases the absorption of SLT energy and so requires less 
energy per spot. This is important as patients with high TM pigmentation are at risk 
of a sustained increase in IOP after SLT as reported by Harasymowycz et al in a series 
of 4 patients. He recommended reducing the SLT energy and treating less of the 
angle at a session to avoid this complication.20 The reason for the greater response 
among high TM pigmentation patients may be related to the SLT technique. In this 
study registrars tended to use similar energy for all patients, regardless of TM 
pigmentation. The energy used may have been optimal for a highly pigmented TM, 
but insufficient for a less pigmented TM. The median 23,5% decrease in IOP in this 
study in the high TM pigmentation group is closer to the IOP reduction one would 
have expected from the studies in table 8. Differences in choice of energy selection 
between different centres, may also explain the inconsistencies between the studies 
mentioned earlier.  
Due to the small sample size of the PCE group, the analysis between PCE and POAG 
groups should be interpreted with caution. Most studies however find equal efficacy 
43 
 
of SLT in PCE glaucoma and POAG as in this study.17 
Although the percentage reduction in IOP between the 180 degree and 360 degree 
groups were similar, the Kaplan-Meier analysis suggests that the duration of IOP 
control was statistically significantly longer for the 180 degree SLT group than for the 
360 degree group (mean 18,7 months vs 8,4 months). Chen compared 90 degree SLT 
and 180 degree SLT and found no statistically significant difference between the 
groups. Chen suggested that the low grade inflammatory response initiated by the 
SLT in the treated portion of the TM may spread through the aqueous to the 
untreated portion and increase the outflow through the entire TM.18 Nager et al11 
compared the IOP reduction of latanoprost with 90, 180 and 360 degrees of SLT. The 
trend was for greater IOP reduction with increasing angle treated. The response 
rates for a 30% and 20% reduction in IOP are presented in the table.  
 
 >20% IOP reduction > 30% IOP reduction 
90 degree SLT 34% 11% 
180 degree SLT 65% 48% 
360 degree SLT 82% 59% 
Table 12: Summary of the response rates for the study by Nager et al for success 
defined as a 20% and a 30% reduction in IOP 11  
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Despite the higher response rates for 360 degree SLT, the difference between the 
180 and 360 degree groups did not reach statistical significance.11 Nager however 
concluded that there is most likely an additional benefit in treating 360 degrees of 
TM rather than just 180 degrees. In the context of above information, this studies 
finding of a longer duration of IOP control with 180 degrees of treatment is difficult 
to explain. It is more likely the result of a confounding factor rather than a real 
finding. Such confounding factors may include clinician factors such as experience or 
techniques; or patient factors. The reasons for clinicians selecting 180 degrees or 
360 degrees of treatment are unknown so selection may have led to patient 
differences between the two groups.  
This result may also be due to the inherent limitations and assumptions of the 
Kaplan-Meier method. The number at risk table underneath the graph indicates that 
at 5 months, 8 of the 16 180 degree patients and 7 of the 29 360 degree patients 
remained in the sample. The low 'number at risk' early in the plot is due either to 
patients no longer being controlled or due to patients being censored early in the 
study. The plot after 5 months should be interpreted with caution as there are 
relatively few patients remaining 'at risk' in that portion of the graph.21 
The number of glaucoma medications was found to have no significant effect on the 
efficacy of SLT. Damji came to a similar conclusion in his study of 18 eyes.7 There are 
however few studies comparing the efficacy of SLT for patients on different numbers 
of medications. One of the commonest indications for SLT is for IOP control for 
patients already on maximal medical therapy.3 The finding of good efficacy of SLT, 
even for patients on high numbers of medication, supports the use of SLT in this 
context.  
There is no study comparing the efficacy of SLT in various stages of glaucoma. 
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Realani after reviewing multiple studies, each on patients at various stages of 
glaucoma suggested that SLT is efficacious at all stages of glaucoma.3 This study 
supports his suggestion. One of the limitations of this study is that visual field 
information was not available for all patients, so staging in some patients was based 
on cup to disc ratio. This measurement is a subjective one and is subject to inter-
observer error. Furthermore cup to disc ratio can be affected by disc size, which was 
not evaluated in this study. This may have led to patients being placed in the 
incorrect group as correlation between cup to disc ratio and visual field performance 
may not be adequate. However, given the very high p values obtained for both the 
analysis of post-SLT IOP and Kaplan-Meier analysis, these limitations are unlikely to 
have affected the results,  
Interest in corneal thickness as a risk factor for glaucoma progression began with the 
ocular hypertension treatment study which showed that patients with ocular 
hypertension were more likely to progress to glaucoma if they had thinner corneas, 
independent of their IOP.22 This finding is more likely related to the effect of corneal 
thickness on IOP measurement, or to susceptibility of the optic nerve to damage in 
patients with thin corneas. As the values used in this analysis were a change in IOP 
rather than an absolute IOP value and optic nerve progression was not assessed, this 
study was unlikely to come across any differences between thin and thick corneas.  
There were no significant differences in the efficacy between high, medium and low 
total SLT energy. The absolute amount of energy used is probably less important 
than using the appropriate energy for a particular patient. A relatively low energy 
level is appropriate for a highly pigmented TM and vice versa. Any correlation 
between the total energy is therefore masked by different TM pigmentations.  
The major limitation of this study stems from its retrospective nature, and therefore 
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from the very heterogeneous patient and clinician mix. The large number of treating 
clinicians, each with different SLT techniques and experience introduced an 
important confounding variable. Clinician’s handling of patients after SLT was also 
varied greatly. Some clinicians increased medical treatment very soon after SLT. 
These patients may have responded if given some more follow up time, but were 
eliminated from further IOP collection as their medication was increased.  
It was difficult to define a criterion for treatment success which would be 
appropriate for all the study patients as the indication for SLT was not always clear 
from the patient notes  
Variability in patients’ medical treatment was also a problem. Variability in supply of 
mediations led to patients either going without a particular medication or using a 
substitute. This in turn could lead to IOP increases which may have affected the 
results.  
Follow up intervals were different for each patient so it was not possible to analyse 
the IOP at a particular time point. The average post-SLT IOP therefore had to be 
used. This measure however also had its limitations as there was great variability in 
follow up time and follow up interval for each patient. For this reason the Kaplan-
Meier analysis was also performed.  
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Conclusion 
The analysis performed has shown that SLT results in a statically significant reduction 
in the IOP of black patients with glaucoma. The mean reduction in the IOP after SLT 
of in this study was 12% which is modest when compared to previously published 
SLT studies. The clinicians which performed SLT on the patients analysed in this study 
were relatively inexperienced compared to the clinicians that would have performed 
SLT on the patients analysed in the previously published studies. This inexperience 
has been highlighted by the observation that the energy used for SLT on the patients 
analysed in this study was not always appropriate for the level of TM pigmentation. 
This may account for the moderate IOP reduction observed in this study. 
Inappropriate energy selection may also account for the greater IOP reduction seen 
in patients with high trabecular meshwork pigmentation.  
In conclusion SLT is effective in treating glaucoma in black patients. Clinicians and 
patients however should be cognisant of the possibility of no response whatsoever, 
and should be aware that a 30% reduction in IOP may only be seen in a minority of 
patients. In addition, this study has highlighted the importance of good technique 
and appropriate energy selection in order to get maximum benefit when SLT is 
performed. 
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